You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SHR-1210

Showing 1 - 25 of 343
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Tumors Trial (SHR-1210)

Not yet recruiting
  • Advanced Tumors
  • SHR-1210
  • (no location specified)
Apr 4, 2023

Recurrent or Metastatic Cervical Cancer Trial in Shanghai (SHR-1210, SHR-1020, Physician's choice chemo)

Active, not recruiting
  • Recurrent or Metastatic Cervical Cancer
  • SHR-1210
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 14, 2022

Triple Negative Breast Cancer Trial in Beijing (SHR-1210 + Apatinib +Fluzoparib)

Completed
  • Triple Negative Breast Cancer
  • SHR-1210 + Apatinib +Fluzoparib
  • Beijing, Beijing, China
    Beijing Cancer Hosptial
Aug 9, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound

Active, not recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
  • Albumin-bound Paclitaxel
  • Wuhan, Hubei, China
    Tongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023

Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib)

Recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 16, 2022

Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)

Active, not recruiting
  • Advanced Primary Liver Cancer
  • Advanced Biliary Tract Carcinoma
  • SHR-1210
  • +3 more
  • Zhengzhou, Henan, China
  • +1 more
Apr 26, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)

Completed
  • Nasopharyngeal Carcinoma
  • SHR-1210
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Esophageal Cancer Trial (Camrelizumab, Apatinib)

Not yet recruiting
  • Esophageal Cancer
  • (no location specified)
Sep 13, 2021

Gastric Cancer, GastroEsophageal Cancer Trial in China (SHR-1210, Capecitabine, Oxaliplatin)

Completed
  • Gastric Cancer
  • GastroEsophageal Cancer
  • SHR-1210
  • +3 more
  • Hefei, Anhui, China
  • +9 more
Jun 30, 2022

Hodgkin Lymphoma, Adult Trial in Beijing (SHR-1210)

Completed
  • Hodgkin Lymphoma, Adult
  • SHR-1210
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2021

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 1, 2022

Biliary Tract Cancer, Cholangiocarcinoma Trial in Nanjing (SHR-1210+GEMOX)

Completed
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Oct 27, 2021

Hepatocellular Carcinoma Trial in Hangzhou (Apatinib Mesylate, Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Jan 16, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in Beijing (SHR-1210, Capecitabine, Oxaliplatin)

Active, not recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • SHR-1210
  • +3 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital, Peking University
Aug 24, 2021

Esophageal Cancer Trial in Tianjin (Camrelizumab, Paclitaxel, Cisplatin)

Active, not recruiting
  • Esophageal Cancer
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 14, 2021

Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

Recruiting
  • Breast Cancer
  • Metastatic Cancer
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
Jul 22, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Advanced Hepatocellular Carcinoma Trial in Nanjing (SHR-1210, FOLFOX4, Placebo)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • SHR-1210
  • +2 more
  • Nanjing, Jiangsu, China
    81 Hospital Nanjing
Feb 9, 2022

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Trial in Shanghai (SHR-1210)

Not yet recruiting
  • Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
  • SHR-1210
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 5, 2021

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Nimotuzumab + SHR-1210)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Nimotuzumab + SHR-1210
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Jul 6, 2021